Jeroen Rovers is the newly named chief medical officer of biopharma company Kiadis Pharma. Prior to this position, he was CMO at Ceronco Biosciences. Rovers is an expert in cell based therapeutics. His experience will support Kiadis in the development of its T-cell immunology treatment for cancer, currently undergoing phase II with the leading candidate ATIR. “I believe ATIR is a truly innovative product and has the potential to become a key part of the next generation treatments of blood cancers”, said Rovers.